Pharmaceutical Pricing and Medical Innovation
Other featured articles
How Would Sharing Rebates at the Point-Of-Sale Affect Beneficiary Cost-Sharing in Medicare Part D?
If cost-sharing were based on net price it would provide meaningful financial relief to many Part D beneficiaries.
The Association Between Drug Rebates and List Prices
Drug rebates and list prices are positively correlated: On average, a $1 increase in rebates is associated with a $1.17 increase in list price.
Sharing Drug Rebates With Medicare Part D Patients: Why And How
The percentage of total Medicare Part D drug spending offset by rebates on branded drugs increased from 11% in 2010 to 25% in 2018.
Are U.S. Health Care Prices Too High, Too Low, or Some Mix of the Two?
Part 1 of a panel series on health care price regulation honoring Uwe E. Reinhardt (1937-2017)
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.